[The risk of bisphosphonate-related osteonecrosis of the jaw].
Bisphosphonates are widely used in the treatment of osteonecrosis and oncology related bone complications. Their use is highly beneficial for the patient, but may be associated with adverse effects. Osteonecrosis of the jaw is an often cited complication of this treatment, but is in practice rarely seen. Its prevalence is low in cases of osteoporosis but a little higher in the oncological setting. Although its pathophysiology is not completely eluci-dated, certain risk factors have been identified such as tooth extraction which often precedes the affection. Management requires a multidisciplinary approach and a conservative treatment is usually preferred. Dealing with this rare condition requires identification of at risk patients so as to apply preventative measures.